Acquired coagulation factor deficiency 1 D68.4 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM D68.4 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of D68.4 - other international versions of ICD-10 D68.4 may differ.
2018/2019 ICD-10-CM Diagnosis Code D68.52. Prothrombin gene mutation. 2016 2017 2018 2019 Billable/Specific Code. D68.52 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
2018/2019 ICD-10-CM Diagnosis Code D68.2. Hereditary deficiency of other clotting factors. 2016 2017 2018 2019 Billable/Specific Code. D68.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Diagnosis Index entries containing back-references to D68.52: Hypercoagulable (state) D68.59 ICD-10-CM Diagnosis Code D68.59. Other primary thrombophilia 2016 2017 2018 2019 2020 Billable/Specific Code Mutation(s) prothrombin gene D68.52 Prothrombin gene mutation D68.52
Prothrombin is a protein in the blood that is required for the blood to clot. It is also called factor II. Blood clots are composed of a combination of blood platelets and a meshwork of the blood clotting protein fibrin. Prothrombin is a blood clotting protein that is needed to form fibrin.
1: Abnormal coagulation profile.
ICD-10-CM Code for Prothrombin gene mutation D68. 52.
Prothrombin gene mutation (or Factor II mutation or Prothrombin G20210A) is an inherited condition that increases your predisposition to develop abnormal blood clots in the veins (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE).
NCD - Partial ThromboplastinTime (PTT) (190.16)
1.
Factor II Mutation (Prothrombin Gene Mutation G20210A) (DNA Analysis)Test IDLAB5668CPT Codes81240Group/Individual TestIndividual (Can also be ordered as a Factor II/Factor V Mutation Panel-Lab12500)LaboratoryMolecular Genetics LaboratoryTube Station308 more rows•Apr 8, 2022
Having the Prothrombin Gene Mutation increases your risk of having a blood clot. If you have one copy of the Prothrombin Gene Mutation (also called being a heterozygote for this gene), you are at around 3 times more at risk of developing a blood clot compared to someone your age who does not have this gene change.
A: When physicians use a prothrombin time test (reported with CPT code 85610) to monitor patients on anticoagulant drugs, Medicare pays the entity that performed the test. Its payment for the test is based on the geographically specific laboratory test fee schedule.
The F2 gene provides instructions for making a protein called prothrombin (also called coagulation factor II). Coagulation factors are a group of related proteins that are essential for normal blood clotting (hemostasis).
The Factor V variant known as Factor V Leiden (or rs6025) is associated with an approximately 300% increased risk in heterozygotes and an up to 8000% increased risk in homozygotes. The Factor II rs1799963 polymorphism (or G20210A) may also independently increase the risk by approximately 200%.
Prothrombin testing is done by taking a blood sample, and using a genetic test to look at the prothrombin gene. The DNA is isolated from blood cells and the prothrombin gene is examined to see if there is a mutation in the DNA code.
A blood coagulation disorder characterized by the complete absence of fibrinogen in the blood, resulting in bleeding. A deficiency of blood coagulation factor v (known as proaccelerin or accelerator globulin or labile factor) leading to a rare hemorrhagic tendency known as owren's disease or parahemophilia.
A usually inherited blood coagulation disorder characterized by the partial or complete absence of fibrinogen in the blood, resulting in bleeding. A very rare autosomal recessive inherited blood coagulation disorder characterized by deficiency of factor v, resulting in bleeding.
This protein is proteolytically cleaved in multiple steps to form the activated serine protease thrombin. The activated thrombin enzyme plays an important role in thrombosis and hemostasis by converting fibrinogen to fibrin during blood clot formation, by stimulating platelet aggregation, and by activating additional coagulation factors. Thrombin also plays a role in cell proliferation, tissue repair, and angiogenesis as well as maintaining vascular integrity during development and postnatal life. Peptides derived from the C-terminus of this protein have antimicrobial activity against E. coli and P. aeruginosa. Mutations in this gene lead to various forms of thrombosis and dysprothrombinemia. Rapid increases in cytokine levels following coronavirus infections can dysregulate the coagulation cascade and produce thrombosis, compromised blood supply, and organ failure. [provided by RefSeq, May 2020]
Thrombin also plays a role in cell proliferation, tissue repair, and angiogenesis as well as maintaining vascular integrity during development and postnatal life. Peptides derived from the C-terminus of this protein have antimicrobial activity against E. coli and P. aeruginosa.
Mutations in this gene lead to various forms of thrombosis and dysprothrombinemia. Rapid increases in cytokine levels following coronavirus infections can dysregulate the coagulation cascade and produce thrombosis, compromised blood supply, and organ failure. [provided by RefSeq, May 2020]
CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
Title XVIII of the Social Security Act, §1833 (e) prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.
The following coding and billing guidance is to be used with its associated Local coverage determination.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.
Genetic testing for these patients is indicated. There may also be benefit to screening pregnant women with a family history of known thrombophilia, as those women found to have a high risk genotype would be offered antenatal prophylactic anticoagulant therapy even in the absence of a personal history of VTE.
However, Medicare will not add coverage of thrombophilia testing for pregnant women because they likely represent a very small group of potential Medicare (disabled) patients.
The presence of hereditary thrombophilia has not been used as a major factor to guide duration of anticoagulation for VTE in these guidelines because evidence from prospective studies suggests that these factors are not major determinates of the risk of recurrence.